View Older Stories View More Recent Stories
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) PT Raised to $96 at Stifel
-
Truist: 'We Remain Buyers of Cytokinetics (CYTK)'
-
Cytokinetics presents aficamten data at cardiology congress
-
Cytokinetics (CYTK) Tops Q2 EPS by 30c, provides guidance
-
Raymond James Assumes, Downgrades Cytokinetics (CYTK) to Market Perform
-
Citi Adjusts North American Focus List
-
Cytokinetics (CYTK) PT Lowered to $53 at JPMorgan
-
Cytokinetics (CYTK) PT Lowered to $84 at Mizuho
-
Stifel Reiterates Buy Rating on Cytokinetics (CYTK)
-
Stifel on Cytokinetics (CYTK): 'we remain confident in a best-in-class opportunity for aficamten'
-
Cytokinetics (CYTK) Announces Positive Topline Results From MAPLE-HCM
-
Cytokinetics (CYTK) PT Lowered to $60 at Evercore ISI
-
Cytokinetics (CYTK) PT Lowered to $80 at Citi
-
Citizens JMP Reiterates Market Outperform Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) Tops Q1 EPS by 1c
-
Citizens JMP Reiterates Market Outperform Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy
-
Barclays Starts Cytokinetics (CYTK) at Overweight
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
H.C. Wainwright on Cytokinetics (CYTK): 'Less Restrictive Label for Camzyos in oHCM; We Still Project Cleaner Label for Aficamten; Reiterate Top Pick'
-
Stifel Reiterates Buy Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) PT Lowered to $54 at BofA Securities
-
Citizens JMP Reiterates Market Outperform Rating on Cytokinetics (CYTK)
-
Piper Sandler: 'What Biotech Names to Own in Market Volatility'
-
Citizens JMP Reiterates Market Outperform Rating on Cytokinetics (CYTK)
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
Cantor Fitzgerald Reiterates Overweight Rating on Cytokinetics (CYTK)
-
Citizens JMP Reiterates Market Outperform Rating on Cytokinetics (CYTK)
-
Raymond James Reiterates Outperform Rating on Cytokinetics (CYTK), PT $81
-
Morgan Stanley Reiterates Overweight Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) Announces Launch of EARTH-HCM
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
Citi Reiterates Buy Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK): FDA has informed Cytokinetics that it does not plan to convene an advisory committee meeting to review the Company’s NDA for aficamten
-
Morgan Stanley Assumes Cytokinetics (CYTK) at Overweight (Yesterday)
-
Cytokinetics (CYTK) Misses Q4 EPS by 4c, provides guidance
-
Stifel Reiterates Buy Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) mentioned at Betaville
-
Morgan Stanley Upgrades Cytokinetics (CYTK) to Overweight
-
Cytokinetics (CYTK) Appoints Robert E. Landry to its Board
-
Citi Starts Cytokinetics (CYTK) at Buy, PT $86
-
JMP Securities Reiterates Market Outperform Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) Announces Recipients of Its Seventh Annual Communications Grant Program
-
Cantor Fitzgerald provides update on Biotechnology stocks
-
Stifel Starts Cytokinetics (CYTK) at Buy
-
Cytokinetics (CYTK) Announces Start of AMBER-HFpEF
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm

